je.st

Home › oral

Tag: oral

Oral fluid testing provides big diagnostic advantages

2015-02-02 20:23:00| National Hog Farmer

By J. Zimmerman, DVM, PHD, Iowa State University, Ames, Iowa Most experts agree that on-farm collection of statistically appropriate numbers of blood or nasal swab specimens from individual pigs is too expensive and requires too much work to be done on a routine basis. The solution could be to switch to oral fluid diagnostic specimens. read more

Tags: big testing oral advantages

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

2014-12-10 14:44:18| Chemicals - Topix.net

Bayer HealthCare and the Drugs for Neglected Diseases initiative have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness . The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

Tags: sign agreement treatment develop

Positive Results with Oral Fluid Sampling for Pigs

2014-10-10 02:00:00| ThePigSite - Industry News

UK - Oral fluid sampling will offer UK pig producers a stress-free way to monitor herd disease levels, using cotton rope for pigs to chew.

Tags: results positive oral fluid

Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis

2014-09-15 19:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. Merck now expects to submit the New Drug Application for odanacatib with the U.S. Food and Drug Administration (FDA) in 2015 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Mercks investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Tracy Ogden, 215-370-5597orInvestors:Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for data study treatment